UY31210A1 - Formulaciones de anticuerpos - Google Patents
Formulaciones de anticuerposInfo
- Publication number
- UY31210A1 UY31210A1 UY31210A UY31210A UY31210A1 UY 31210 A1 UY31210 A1 UY 31210A1 UY 31210 A UY31210 A UY 31210A UY 31210 A UY31210 A UY 31210A UY 31210 A1 UY31210 A1 UY 31210A1
- Authority
- UY
- Uruguay
- Prior art keywords
- formulations
- temperature
- standard formulation
- antibodies
- antibody formulations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
Abstract
Esta invención se refiere a formulaciones de anticuerpo estables a la temperatura y la cizalladura, que son más estables comparardas con una formulación estándar (tal como citrato 30mM, NaCI 100 mM, pH 6,5). Las formulaciones de anticuerpo estables a la temperatura y la cizalladura de la presente invención mostraron menor precipitación cuando se sometían a condiciones de tensión, mientras que la formulación estándar se había agregado. Este resultado era impredecible porque termodinámicamente las dos formulaciones son similares, como se ve por sus perfiles de DSC (calorimetría diferencial de barrido).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94822007P | 2007-07-06 | 2007-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31210A1 true UY31210A1 (es) | 2009-01-30 |
Family
ID=40228991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY31210A UY31210A1 (es) | 2007-07-06 | 2008-07-04 | Formulaciones de anticuerpos |
Country Status (38)
Country | Link |
---|---|
US (2) | US20110020328A1 (es) |
EP (2) | EP2889310B1 (es) |
JP (1) | JP5529017B2 (es) |
KR (2) | KR20100038092A (es) |
CN (1) | CN101820912B (es) |
AR (2) | AR067455A1 (es) |
AU (1) | AU2008275278B2 (es) |
BR (2) | BR122020026978B1 (es) |
CA (1) | CA2692681C (es) |
CL (1) | CL2008001984A1 (es) |
CO (1) | CO6270340A2 (es) |
CR (1) | CR11249A (es) |
CY (2) | CY1118419T1 (es) |
DK (2) | DK2170388T3 (es) |
DO (1) | DOP2010000001A (es) |
EA (1) | EA017994B1 (es) |
ES (2) | ES2663504T3 (es) |
FR (1) | FR21C1040I1 (es) |
HK (2) | HK1207652A1 (es) |
HR (2) | HRP20170033T1 (es) |
HU (3) | HUE038501T2 (es) |
IL (1) | IL202950A (es) |
JO (1) | JO3219B1 (es) |
LT (3) | LT2889310T (es) |
MA (1) | MA31471B1 (es) |
MX (1) | MX2010000017A (es) |
NO (2) | NO2889310T3 (es) |
NZ (1) | NZ582250A (es) |
PE (1) | PE20090738A1 (es) |
PL (2) | PL2889310T3 (es) |
PT (2) | PT2889310T (es) |
SI (2) | SI2170388T1 (es) |
TR (1) | TR201802928T4 (es) |
TW (2) | TWI515204B (es) |
UA (1) | UA107557C2 (es) |
UY (1) | UY31210A1 (es) |
WO (1) | WO2009009407A1 (es) |
ZA (1) | ZA200909107B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
EP2173163A4 (en) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
KR20120130757A (ko) | 2010-02-26 | 2012-12-03 | 노보 노르디스크 에이/에스 | 안정한 항체 함유 조성물 |
CA2976671C (en) | 2010-03-01 | 2021-01-12 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
CA2800188A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
AU2012243126A1 (en) * | 2011-04-07 | 2013-10-17 | Glaxosmithkline Llc | Formulations with reduced viscosity |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
KR102493433B1 (ko) * | 2011-05-02 | 2023-01-27 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
CN111973484A (zh) | 2013-03-12 | 2020-11-24 | 普莱玛疗法公司 | 包含螯合剂和碱的牙用组合物 |
EP2805730A1 (en) * | 2013-05-21 | 2014-11-26 | Bergen Teknologioverforing AS | Nitric oxide donor for the treatment of chronic fatigue syndrome |
WO2015162504A1 (en) | 2014-04-23 | 2015-10-29 | Novartis Ag | Novel dosing and uses of ofatumumab |
WO2016189491A1 (en) * | 2015-05-28 | 2016-12-01 | Glaxosmithkline Intellectual Property Development Limited | Novel formulation |
WO2017136433A1 (en) * | 2016-02-03 | 2017-08-10 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
PL3497132T3 (pl) * | 2016-08-15 | 2020-11-30 | Novartis Ag | Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu |
WO2018179138A1 (ja) * | 2017-03-29 | 2018-10-04 | 持田製薬株式会社 | 抗体含有液体製剤 |
EP3606964A4 (en) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
US11513046B2 (en) * | 2018-02-09 | 2022-11-29 | Championx Usa Inc. | Flowability testing systems and methods |
AU2020347474A1 (en) | 2019-09-11 | 2022-04-07 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
ES2957112T3 (es) | 2019-09-11 | 2024-01-11 | Novartis Ag | Tratamiento del RMS mediante cambio de terapia |
CN112675126A (zh) * | 2019-10-18 | 2021-04-20 | 百奥泰生物制药股份有限公司 | 抗cd20抗体制剂及其应用 |
AU2021253674A1 (en) | 2020-04-09 | 2022-11-03 | Novartis Ag | Ofatumumab for treating MS while maintaining serum IgG |
JP7057954B2 (ja) * | 2020-09-03 | 2022-04-21 | 国立大学法人大阪大学 | 改善された保存安定性を有するタンパク質含有液体製剤 |
IL307464A (en) | 2021-04-14 | 2023-12-01 | Novartis Ag | OFATUMUMAB for the treatment of multiple sclerosis in Asian patients |
WO2023020802A1 (en) | 2021-08-16 | 2023-02-23 | Novartis Ag | Ofatumumab for treating pediatric ms |
WO2023204554A1 (ko) * | 2022-04-20 | 2023-10-26 | 주식회사 알토스바이오로직스 | 오크렐리주맙을 포함하는 약학적 조성물과 그의 용도 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4816401A (en) * | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
EP0999853B1 (en) * | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
WO2001024814A1 (en) * | 1999-10-04 | 2001-04-12 | Chiron Corporation | Stabilized liquid polypeptide-containing pharmaceutical compositions |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2476166C (en) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
MXPA04008215A (es) * | 2002-02-27 | 2004-11-26 | Immunex Corp | Formulacion polipeptidica. |
EP1551875A4 (en) * | 2002-06-21 | 2006-06-28 | Biogen Idec Inc | TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF |
DK3284753T3 (da) * | 2002-10-17 | 2021-07-05 | Genmab As | Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose |
WO2004058797A2 (en) * | 2002-12-16 | 2004-07-15 | Medarex, Inc. | Human monoclonal antibodies against interleukin 8 (il-8) |
US8084582B2 (en) * | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
EP1871806A2 (en) * | 2005-03-08 | 2008-01-02 | Pharmacia & Upjohn Company LLC | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
AU2006296399B2 (en) * | 2005-09-30 | 2011-01-20 | Medimmune Limited | Interleukin-13 antibody composition |
UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
EP2173163A4 (en) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
-
2008
- 2008-03-07 UA UAA201001165A patent/UA107557C2/ru unknown
- 2008-07-03 MX MX2010000017A patent/MX2010000017A/es active IP Right Grant
- 2008-07-03 WO PCT/US2008/069125 patent/WO2009009407A1/en active Application Filing
- 2008-07-03 EA EA201070105A patent/EA017994B1/ru not_active IP Right Cessation
- 2008-07-03 HU HUE15155712A patent/HUE038501T2/hu unknown
- 2008-07-03 SI SI200831738A patent/SI2170388T1/sl unknown
- 2008-07-03 BR BR122020026978-2A patent/BR122020026978B1/pt active IP Right Grant
- 2008-07-03 PL PL15155712T patent/PL2889310T3/pl unknown
- 2008-07-03 PT PT151557121T patent/PT2889310T/pt unknown
- 2008-07-03 KR KR1020107000148A patent/KR20100038092A/ko not_active Application Discontinuation
- 2008-07-03 JP JP2010516158A patent/JP5529017B2/ja active Active
- 2008-07-03 KR KR1020157019741A patent/KR101670454B1/ko active IP Right Grant
- 2008-07-03 EP EP15155712.1A patent/EP2889310B1/en active Active
- 2008-07-03 AU AU2008275278A patent/AU2008275278B2/en active Active
- 2008-07-03 BR BRPI0814003-0A patent/BRPI0814003B1/pt active IP Right Grant
- 2008-07-03 ES ES15155712.1T patent/ES2663504T3/es active Active
- 2008-07-03 CA CA2692681A patent/CA2692681C/en active Active
- 2008-07-03 DK DK08781323.4T patent/DK2170388T3/en active
- 2008-07-03 US US12/667,890 patent/US20110020328A1/en not_active Abandoned
- 2008-07-03 PT PT87813234T patent/PT2170388T/pt unknown
- 2008-07-03 EP EP08781323.4A patent/EP2170388B1/en active Active
- 2008-07-03 PL PL08781323T patent/PL2170388T3/pl unknown
- 2008-07-03 CN CN200880105866.1A patent/CN101820912B/zh active Active
- 2008-07-03 DK DK15155712.1T patent/DK2889310T3/en active
- 2008-07-03 TR TR2018/02928T patent/TR201802928T4/tr unknown
- 2008-07-03 NO NO15155712A patent/NO2889310T3/no unknown
- 2008-07-03 SI SI200831928T patent/SI2889310T1/en unknown
- 2008-07-03 LT LTEP15155712.1T patent/LT2889310T/lt unknown
- 2008-07-03 NZ NZ582250A patent/NZ582250A/en unknown
- 2008-07-03 LT LTEP08781323.4T patent/LT2170388T/lt unknown
- 2008-07-03 HU HUE08781323A patent/HUE031288T2/hu unknown
- 2008-07-03 JO JOP/2008/0312A patent/JO3219B1/ar active
- 2008-07-03 ES ES08781323.4T patent/ES2610821T3/es active Active
- 2008-07-04 TW TW097125246A patent/TWI515204B/zh active
- 2008-07-04 UY UY31210A patent/UY31210A1/es not_active Application Discontinuation
- 2008-07-04 CL CL2008001984A patent/CL2008001984A1/es unknown
- 2008-07-04 TW TW104128324A patent/TWI612060B/zh active
- 2008-07-04 AR ARP080102910A patent/AR067455A1/es unknown
- 2008-07-04 PE PE2008001136A patent/PE20090738A1/es active IP Right Grant
-
2009
- 2009-12-21 ZA ZA2009/09107A patent/ZA200909107B/en unknown
- 2009-12-24 IL IL202950A patent/IL202950A/en active IP Right Grant
- 2009-12-30 CO CO09149371A patent/CO6270340A2/es active IP Right Grant
- 2009-12-30 MA MA32460A patent/MA31471B1/fr unknown
-
2010
- 2010-01-05 DO DO2010000001A patent/DOP2010000001A/es unknown
- 2010-02-02 CR CR11249A patent/CR11249A/es unknown
- 2010-09-02 HK HK15108178.0A patent/HK1207652A1/xx unknown
- 2010-09-02 HK HK10108319.5A patent/HK1141979A1/zh unknown
-
2015
- 2015-02-19 US US14/625,881 patent/US20150158951A1/en not_active Abandoned
-
2017
- 2017-01-10 HR HRP20170033TT patent/HRP20170033T1/hr unknown
- 2017-01-12 CY CY20171100043T patent/CY1118419T1/el unknown
- 2017-08-29 AR ARP170102392A patent/AR109461A2/es not_active Application Discontinuation
-
2018
- 2018-03-14 HR HRP20180440TT patent/HRP20180440T1/hr unknown
- 2018-03-20 CY CY20181100325T patent/CY1120047T1/el unknown
-
2021
- 2021-09-13 NO NO2021036C patent/NO2021036I1/no unknown
- 2021-09-14 FR FR21C1040C patent/FR21C1040I1/fr active Active
- 2021-09-15 HU HUS2100038C patent/HUS2100038I1/hu unknown
- 2021-09-15 LT LTPA2021520C patent/LTPA2021520I1/lt unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31210A1 (es) | Formulaciones de anticuerpos | |
CY1112781T1 (el) | 2'-φθορο-2'-δεοξυτετραϋδροουριδινες ως αναστολεις αποαμινασης κυτιδινης | |
BR112014000688A2 (pt) | composições pesticidas e processos relacionados com as mesmas | |
CY1115893T1 (el) | Anti-μολυσματικες πυριμιδινες και χρησεις αυτων | |
CY1112653T1 (el) | Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης | |
GT200600084A (es) | Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen | |
UY32557A (es) | Composición endulzante que comprende una forma de rebaudiosida a de alta solubilidad y método para su producción | |
BRPI0810332A2 (pt) | "politioéter envolvido com amina/hidroxi" | |
TR201907244T4 (tr) | Anti̇parazi̇ti̇k di̇hi̇droazol bi̇leşi̇mleri̇ | |
NI201200023A (es) | Derivados de 5-fluoropirimidinona | |
CO6741214A2 (es) | Composiciones pesticidas y procesos relacionados | |
ATE528989T1 (de) | Kristalline feste rasagilin-base | |
BRPI0715579A2 (pt) | "composto, composição farmacêutica e uso de um composto" | |
GT200600346A (es) | Nueva fórmula cristalina v de la agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen | |
RS54217B1 (en) | SOME TRIAZOLOPIRAZINS, THEIR COMPOSITIONS AND THE METHODS OF USING THEM | |
EA200870217A1 (ru) | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции | |
CY1116048T1 (el) | Μια κρυσταλλικη μορφη τιγεκυκλινης και διαδικασιες για την παρασκευη της | |
BRPI1015043A2 (pt) | derivados de diazahomoadamantano e métodos de uso dos mesmos | |
ATE509931T1 (de) | Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür | |
EA201071183A1 (ru) | Безводная кристаллическая форма малеата орвепитанта | |
MA31840B1 (fr) | Nouvelles compositions a base de taxoides | |
BRPI0603784A (pt) | lubrificante pessoal vaporizável | |
CY1116319T1 (el) | Συνθεσεις που περιλαμβανουν core-1 θετικο μικροοργανισμο και χρηση αυτων για την αντιμετωπιση ή προφυλαξη απο ογκους | |
ATE552832T1 (de) | Antidepressivum-propharmaka | |
PA8772401A1 (es) | Macrólidos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20200710 |